@article{01f9394d51f940a1a3375475e086198e,
title = "Contemporary diagnosis and management of severe tricuspid regurgitation",
abstract = "Many novel percutaneous interventions are being developed for application in the tricuspid valve position. At the present time in the United States, there are no commercially available transcathter devices for this application. This article reviews the growing evidence for diagnosing, imaging, and treating severe tricuspid regurgitation as well as the surgical and transcatheter options that are under current development and in various stages of clinical trials.",
keywords = "replacement, transcatheter valve repair, tricuspid regurgitation",
author = "Firas Zahr and Scott Chadderdon and Howard Song and Edward Sako and Cristina Fuss and Bailey, {Steven R.} and Joaquin Cigarroa",
note = "Funding Information: Cerclage‐TR block is being refined with funding from the National Institutes of Health to implant a leaflet extension at the septal location of the TV. The concept is based on the Mitral Loop Cerclage Annuloplasty device (Tau‐PNU Medical city, state, nation), which has been reported to reduce MR in four out of five patients in its first in human feasibility study. The procedure involves placing the device anchor in the subclavian vein and creating a 360° loop around the mitral annulus in the pericardium. One arm of the device enters the coronary sinus, septal vein and then perforates the interventricular septum to enter the right ventricular outflow tract. From the RVOT it is snared and externalized via the femoral vein. Subsequently, the second arm of the device enter through right atrium and is placed underneath the sepal tricuspid leaflet. The key difference between the tricuspid and mitral devices is that the tricuspid Cerclage device uses a septal leaflet extension which improves the leaflet contact and reduces the coaptation gap. In the initial preclinical ( = 5) and animal lab data ( = 5), showed 1 grade reduction in TR even in the destructive TR model. This technology could offer an advantage for patients with concomitant severe TR and MR to handle both valvular pathology simultaneously. 67 n n 68 Publisher Copyright: {\textcopyright} 2022 Wiley Periodicals LLC.",
year = "2022",
month = oct,
day = "1",
doi = "10.1002/ccd.30364",
language = "English (US)",
volume = "100",
pages = "646--661",
journal = "Catheterization and Cardiovascular Interventions",
issn = "1522-1946",
publisher = "Wiley-Liss Inc.",
number = "4",
}